Post-Traumatic Stress Disorder
Conditions
Brief summary
This is a randomized, double-blind, placebo-controlled study, evaluating the effects of BNC210 versus placebo on the symptoms of Post-Traumatic Stress Disorder, as measured by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). The secondary objectives of the study are to evaluate the effects of BNC210 on anxiety, depression, global functioning and patient reported outcomes in patients with PTSD. Safety and tolerability of BNC210 will also be assessed. Study participants will receive 12 weeks of blinded treatment followed by a 3 week follow-up period.
Interventions
DRUGBNC210
DRUGPlacebo
Sponsors
Bionomics Limited
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Double blind
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * Signed and dated informed consent. * Male or female between 18 and 70 years of age, inclusive. * Diagnosed with current PTSD as defined by the CAPS-5 for DSM-5. * Currently not using any psychiatric medications except for: * No more than one selective serotonin reuptake inhibitor (SSRI) (fluvoxamine is excluded) or serotonin noradrenaline reuptake inhibitor (SNRI) within the licensed prescribing dose range. Subjects must have been on a stable dose for at least 3 months prior and through Screening, with the intent to remain on the same dose through to Week 16. * As needed (PRN) use of benzodiazepines (BZD) at a frequency not exceeding 2 days per week in the 3 months prior to Screening. The total dose must not exceed 30 mg/day in diazepam equivalents. * Subjects not currently receiving psychotherapy except long term supportive counseling or subjects that have received intensive regular psychotherapy for a minimum of three months prior to Screening. * Females of childbearing potential must have a negative serum pregnancy. Females not of childbearing potential must be postmenopausal. Sterilized male patients must be at least 1 year post-vasectomy to be considered of non-child bearing potential. Females and males of childbearing potential must agree to use two effective methods of contraception. Key
Exclusion criteria
* Current and ongoing exposure to the trauma that caused the PTSD. * Failed more than three trials of antidepressant medication(s) prescribed for the treatment of PTSD. Each trial must have lasted at least 6 weeks to be considered a failed attempt. A trial that was terminated due to intolerability or side effects does not constitute a failed attempt. * The use of psychiatric medications within 2 weeks of Screening except for SSRIs, SNRIs or limited PRN BZD use as per inclusion criterion 4. Restricted psychiatric medications include (but are not limited to) antidepressants not allowed by inclusion criterion 4, antianxiety drugs (except limited BZD use per inclusion criterion 4), mood stabilizers, stimulants, antipsychotics, hypnotics and acetylcholinesterase inhibitors. * History of significant traumatic brain injury. * Depression as measured by Montgomery-Äsberg depression scale (MADRS) rating \> 23. * Bipolar and psychotic disorders as identified at Screening using the MINI International Neuropsychiatry Interview (V7.0) (M.I.N.I). * A score ≥ 7 on the McLean Screening Instrument for Borderline Personality Disorder (MSI-BPD) at Screening. * History of seizure disorders, uncontrolled sleep apnoea or severe neurologic disease. * Increased risk of suicide, defined as: * Any previous suicide attempt disclosed by the participant at Screening using the Columbia Suicide Severity Rating Scale (C-SSRS). * Any suicidal ideation with intent (yes to item 4 and / or 5) or suicidal behavior in the past year, as captured at Screening using the C-SSRS. * A score \> 4 on item 10 of the MADRS at Screening. * The use of alprazolam or flunitrazepam within 3 months of Screening. * Any clinically significant abnormalities in laboratory test results, vitals signs, or ECG at Screening. * Positive result for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C (HCV) at Screening. * Any moderate to severe substance use disorder (any type) in the 12 months prior to Screening as identified by the DSM-5 using the M.I.N.I (V7.0). * Current Australian serving Defense personnel or any member of the US military currently serving on active duty. * Participants involved with ongoing insurance or workplace claims that in the opinion of the Investigator are likely to have an impact on the mental health, presentation or capacity of the patient to engage in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinician-Administered PTSD Scale for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (CAPS-5), Total Symptom Severity Score | 12 weeks. | Investigator-rated PTSD symptom severity. The range for the Clinician-Administered PTSD Scale for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (CAPS-5)Total Symptom Severity Score is 0-80, with a higher score meaning a higher severity of disease. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Montgomery- Åsberg Depression Rating Scale (MADRS). | 12 weeks. | Depression severity. The range for the Montgomery- Åsberg Depression Rating Scale (MADRS) is 0-60, with a higher score meaning a higher severity of disease. |
| Hamilton Anxiety Rating Scale (HAM-A). | 12 weeks | Anxiety severity. The range for the Hamilton Anxiety Rating Scale (HAM-A) is 0-56, with a higher score meaning a higher severity of disease. |
| Clinical Global Impressions - Severity Scale (CGI-S). | 12 weeks | Clinician's assessment of global symptom severity using the Clinical Global Impressions - Severity Scale (CGI-S). |
| Clinical Global Impressions - Improvement Scale (CGI-I). | 12 weeks | Clinician's assessment of global symptom improvement using the Clinical Global Impressions - Improvement Scale (CGI-I). |
| Patient Global Impressions - Severity Scale (PGI-S). | 12 weeks. | Self-reported global symptom severity using the Patient Global Impressions - Severity Scale (CGI-S). |
| Post-Traumatic Stress Disorder (PTSD) Checklist for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (PCL-5). | 12 weeks. | Self-reported PTSD symptom severity. The range for the Post-Traumatic Stress Disorder (PTSD) Checklist for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (PCL-5) Symptom Severity Score is 0-80, with a higher score meaning a higher severity of disease. |
| Assessment of Quality of Life (AQoL-8D). | 12 weeks. | Quality of Life. The range for the Assessment of Quality of Life (AQoL-8D) score is 35-176, with a higher score meaning a lower quality of life. |
| Social Functioning: Sheehan Disability Scale (SDS). | 12 weeks. | Social functioning. The range for the Total Score on the Sheehan Disability Scale (SDS) is 0-30, with a higher score meaning a higher degree of impairment. |
| Sleep Monitoring: Pittsburgh Sleep Quality Index (PSQI). | 12 weeks. | Sleep quality and duration. The range for the Pittsburgh Sleep Quality Index (PSQI) score is 0-21, with a higher score meaning a worse level of sleep quality |
| CANTAB (Cambridge Neuropsychological Test Automated Battery) Cognitive Assessment | 12 Weeks | The CANTAB global composite score is based on the Z scores for CANTAB outcome measures (PAL first attempt memory score (PALFAMS), PAL total errors adjusted (PALTEA), SWM between errors (SWMBE), SWM strategy (SWMS), RVP A' prime (RVPA), RVP median latency (RVPMDL). Specifically, the global composite score of cognitive function is as follows: CANTAB global composite score of cognitive function = (ZPALFAMS + ZPALTEA + ZSWMBE + ZSWMS + ZRVPA + ZRVPMDL) /8 (higher is better) A Z-score of 0 represents the population mean. A Z-score above 0 indicates cognition higher than the population mean and Z-score below 0 indicates cognition lower than the population mean |
| Patient Global Impression - Improvement Scale (PGI-I). | 12 weeks. | Self-reported global symptom improvement using the Patient Global Impression - Improvement Scale (PGI-I). |
Countries
Australia, United States
Participant flow
Pre-assignment details
193 participants were enrolled into the study and randomized to one of the 4 treatment arms. However, 1 participant withdrew from the study prior to beginning treatment with study IP and hence is not included in the overall number of 192 participants who received study IP and for which post-baseline assessments were performed.
Participants by arm
| Arm | Count |
|---|---|
| BNC210 600 mg b.i.d. Suspension administered orally for 12 weeks. | 48 |
| BNC210 300 mg b.i.d. Suspension administered orally for 12 weeks. | 48 |
| BNC210 150 mg b.i.d. Suspension administered orally for 12 weeks. | 47 |
| Placebo b.i.d. Suspension administered orally for 12 weeks. | 49 |
| Total | 192 |
Baseline characteristics
| Characteristic | BNC210 600 mg b.i.d. | BNC210 300 mg b.i.d. | BNC210 150 mg b.i.d. | Placebo b.i.d. | Total |
|---|---|---|---|---|---|
| Age, Categorical <=18 years | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 2 Participants |
| Age, Categorical >=65 years | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Age, Categorical Between 18 and 65 years | 46 Participants | 48 Participants | 46 Participants | 49 Participants | 189 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 16 Participants | 11 Participants | 8 Participants | 10 Participants | 45 Participants |
| Race (NIH/OMB) More than one race | 1 Participants | 1 Participants | 2 Participants | 3 Participants | 7 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 1 Participants | 1 Participants | 2 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 1 Participants | 0 Participants | 1 Participants | 3 Participants |
| Race (NIH/OMB) White | 30 Participants | 35 Participants | 36 Participants | 34 Participants | 135 Participants |
| Region of Enrollment Australia | 7 participants | 7 participants | 6 participants | 11 participants | 31 participants |
| Region of Enrollment United States | 41 participants | 41 participants | 41 participants | 38 participants | 161 participants |
| Sex: Female, Male Female | 25 Participants | 26 Participants | 31 Participants | 30 Participants | 112 Participants |
| Sex: Female, Male Male | 23 Participants | 22 Participants | 16 Participants | 19 Participants | 80 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 48 | 0 / 48 | 0 / 47 | 0 / 49 |
| other Total, other adverse events | 31 / 48 | 42 / 48 | 30 / 47 | 45 / 49 |
| serious Total, serious adverse events | 0 / 48 | 1 / 48 | 0 / 47 | 1 / 49 |
Outcome results
Primary
Clinician-Administered PTSD Scale for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (CAPS-5), Total Symptom Severity Score
Investigator-rated PTSD symptom severity. The range for the Clinician-Administered PTSD Scale for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (CAPS-5)Total Symptom Severity Score is 0-80, with a higher score meaning a higher severity of disease.
Time frame: 12 weeks.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| BNC210 600 mg b.i.d. | Clinician-Administered PTSD Scale for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (CAPS-5), Total Symptom Severity Score | 15.26 score on a scale |
| BNC210 300 mg b.i.d. | Clinician-Administered PTSD Scale for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (CAPS-5), Total Symptom Severity Score | 16.62 score on a scale |
| BNC210 150 mg b.i.d. | Clinician-Administered PTSD Scale for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (CAPS-5), Total Symptom Severity Score | 19.76 score on a scale |
| Placebo b.i.d. | Clinician-Administered PTSD Scale for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (CAPS-5), Total Symptom Severity Score | 14.57 score on a scale |
Secondary
Assessment of Quality of Life (AQoL-8D).
Quality of Life. The range for the Assessment of Quality of Life (AQoL-8D) score is 35-176, with a higher score meaning a lower quality of life.
Time frame: 12 weeks.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| BNC210 600 mg b.i.d. | Assessment of Quality of Life (AQoL-8D). | 77.95 score on a scale |
| BNC210 300 mg b.i.d. | Assessment of Quality of Life (AQoL-8D). | 76.79 score on a scale |
| BNC210 150 mg b.i.d. | Assessment of Quality of Life (AQoL-8D). | 85.47 score on a scale |
| Placebo b.i.d. | Assessment of Quality of Life (AQoL-8D). | 81.05 score on a scale |
Secondary
CANTAB (Cambridge Neuropsychological Test Automated Battery) Cognitive Assessment
The CANTAB global composite score is based on the Z scores for CANTAB outcome measures (PAL first attempt memory score (PALFAMS), PAL total errors adjusted (PALTEA), SWM between errors (SWMBE), SWM strategy (SWMS), RVP A' prime (RVPA), RVP median latency (RVPMDL). Specifically, the global composite score of cognitive function is as follows: CANTAB global composite score of cognitive function = (ZPALFAMS + ZPALTEA + ZSWMBE + ZSWMS + ZRVPA + ZRVPMDL) /8 (higher is better) A Z-score of 0 represents the population mean. A Z-score above 0 indicates cognition higher than the population mean and Z-score below 0 indicates cognition lower than the population mean
Time frame: 12 Weeks
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| BNC210 600 mg b.i.d. | CANTAB (Cambridge Neuropsychological Test Automated Battery) Cognitive Assessment | 0.06 Composite Z score |
| BNC210 300 mg b.i.d. | CANTAB (Cambridge Neuropsychological Test Automated Battery) Cognitive Assessment | 0.12 Composite Z score |
| BNC210 150 mg b.i.d. | CANTAB (Cambridge Neuropsychological Test Automated Battery) Cognitive Assessment | 0.18 Composite Z score |
| Placebo b.i.d. | CANTAB (Cambridge Neuropsychological Test Automated Battery) Cognitive Assessment | 0.02 Composite Z score |
Secondary
Clinical Global Impressions - Improvement Scale (CGI-I).
Clinician's assessment of global symptom improvement using the Clinical Global Impressions - Improvement Scale (CGI-I).
Time frame: 12 weeks
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| BNC210 600 mg b.i.d. | Clinical Global Impressions - Improvement Scale (CGI-I). | Very Much Improved/Much Improved | 22 Participants |
| BNC210 600 mg b.i.d. | Clinical Global Impressions - Improvement Scale (CGI-I). | Other | 11 Participants |
| BNC210 300 mg b.i.d. | Clinical Global Impressions - Improvement Scale (CGI-I). | Other | 16 Participants |
| BNC210 300 mg b.i.d. | Clinical Global Impressions - Improvement Scale (CGI-I). | Very Much Improved/Much Improved | 23 Participants |
| BNC210 150 mg b.i.d. | Clinical Global Impressions - Improvement Scale (CGI-I). | Very Much Improved/Much Improved | 15 Participants |
| BNC210 150 mg b.i.d. | Clinical Global Impressions - Improvement Scale (CGI-I). | Other | 18 Participants |
| Placebo b.i.d. | Clinical Global Impressions - Improvement Scale (CGI-I). | Very Much Improved/Much Improved | 19 Participants |
| Placebo b.i.d. | Clinical Global Impressions - Improvement Scale (CGI-I). | Other | 11 Participants |
Secondary
Clinical Global Impressions - Severity Scale (CGI-S).
Clinician's assessment of global symptom severity using the Clinical Global Impressions - Severity Scale (CGI-S).
Time frame: 12 weeks
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| BNC210 600 mg b.i.d. | Clinical Global Impressions - Severity Scale (CGI-S). | Severely ill | 0 Participants |
| BNC210 600 mg b.i.d. | Clinical Global Impressions - Severity Scale (CGI-S). | Markedly ill | 1 Participants |
| BNC210 600 mg b.i.d. | Clinical Global Impressions - Severity Scale (CGI-S). | Moderately ill | 9 Participants |
| BNC210 600 mg b.i.d. | Clinical Global Impressions - Severity Scale (CGI-S). | Normal, not at all ill | 10 Participants |
| BNC210 600 mg b.i.d. | Clinical Global Impressions - Severity Scale (CGI-S). | Among the most extremely ill patients | 0 Participants |
| BNC210 600 mg b.i.d. | Clinical Global Impressions - Severity Scale (CGI-S). | Borderline mentally ill | 5 Participants |
| BNC210 600 mg b.i.d. | Clinical Global Impressions - Severity Scale (CGI-S). | Mildly ill | 8 Participants |
| BNC210 300 mg b.i.d. | Clinical Global Impressions - Severity Scale (CGI-S). | Markedly ill | 2 Participants |
| BNC210 300 mg b.i.d. | Clinical Global Impressions - Severity Scale (CGI-S). | Mildly ill | 16 Participants |
| BNC210 300 mg b.i.d. | Clinical Global Impressions - Severity Scale (CGI-S). | Borderline mentally ill | 3 Participants |
| BNC210 300 mg b.i.d. | Clinical Global Impressions - Severity Scale (CGI-S). | Moderately ill | 13 Participants |
| BNC210 300 mg b.i.d. | Clinical Global Impressions - Severity Scale (CGI-S). | Among the most extremely ill patients | 0 Participants |
| BNC210 300 mg b.i.d. | Clinical Global Impressions - Severity Scale (CGI-S). | Normal, not at all ill | 5 Participants |
| BNC210 300 mg b.i.d. | Clinical Global Impressions - Severity Scale (CGI-S). | Severely ill | 0 Participants |
| BNC210 150 mg b.i.d. | Clinical Global Impressions - Severity Scale (CGI-S). | Mildly ill | 8 Participants |
| BNC210 150 mg b.i.d. | Clinical Global Impressions - Severity Scale (CGI-S). | Severely ill | 2 Participants |
| BNC210 150 mg b.i.d. | Clinical Global Impressions - Severity Scale (CGI-S). | Normal, not at all ill | 5 Participants |
| BNC210 150 mg b.i.d. | Clinical Global Impressions - Severity Scale (CGI-S). | Borderline mentally ill | 6 Participants |
| BNC210 150 mg b.i.d. | Clinical Global Impressions - Severity Scale (CGI-S). | Moderately ill | 9 Participants |
| BNC210 150 mg b.i.d. | Clinical Global Impressions - Severity Scale (CGI-S). | Markedly ill | 3 Participants |
| BNC210 150 mg b.i.d. | Clinical Global Impressions - Severity Scale (CGI-S). | Among the most extremely ill patients | 0 Participants |
| Placebo b.i.d. | Clinical Global Impressions - Severity Scale (CGI-S). | Borderline mentally ill | 6 Participants |
| Placebo b.i.d. | Clinical Global Impressions - Severity Scale (CGI-S). | Among the most extremely ill patients | 0 Participants |
| Placebo b.i.d. | Clinical Global Impressions - Severity Scale (CGI-S). | Markedly ill | 1 Participants |
| Placebo b.i.d. | Clinical Global Impressions - Severity Scale (CGI-S). | Normal, not at all ill | 10 Participants |
| Placebo b.i.d. | Clinical Global Impressions - Severity Scale (CGI-S). | Severely ill | 1 Participants |
| Placebo b.i.d. | Clinical Global Impressions - Severity Scale (CGI-S). | Moderately ill | 7 Participants |
| Placebo b.i.d. | Clinical Global Impressions - Severity Scale (CGI-S). | Mildly ill | 5 Participants |
Secondary
Hamilton Anxiety Rating Scale (HAM-A).
Anxiety severity. The range for the Hamilton Anxiety Rating Scale (HAM-A) is 0-56, with a higher score meaning a higher severity of disease.
Time frame: 12 weeks
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| BNC210 600 mg b.i.d. | Hamilton Anxiety Rating Scale (HAM-A). | 9.03 score on a scale |
| BNC210 300 mg b.i.d. | Hamilton Anxiety Rating Scale (HAM-A). | 9.94 score on a scale |
| BNC210 150 mg b.i.d. | Hamilton Anxiety Rating Scale (HAM-A). | 10.55 score on a scale |
| Placebo b.i.d. | Hamilton Anxiety Rating Scale (HAM-A). | 7.94 score on a scale |
Secondary
Montgomery- Åsberg Depression Rating Scale (MADRS).
Depression severity. The range for the Montgomery- Åsberg Depression Rating Scale (MADRS) is 0-60, with a higher score meaning a higher severity of disease.
Time frame: 12 weeks.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| BNC210 600 mg b.i.d. | Montgomery- Åsberg Depression Rating Scale (MADRS). | 9.48 score on a scale |
| BNC210 300 mg b.i.d. | Montgomery- Åsberg Depression Rating Scale (MADRS). | 10.25 score on a scale |
| BNC210 150 mg b.i.d. | Montgomery- Åsberg Depression Rating Scale (MADRS). | 12.16 score on a scale |
| Placebo b.i.d. | Montgomery- Åsberg Depression Rating Scale (MADRS). | 8.94 score on a scale |
Secondary
Patient Global Impression - Improvement Scale (PGI-I).
Self-reported global symptom improvement using the Patient Global Impression - Improvement Scale (PGI-I).
Time frame: 12 weeks.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| BNC210 600 mg b.i.d. | Patient Global Impression - Improvement Scale (PGI-I). | Very Much/Much Improved | 17 Participants |
| BNC210 600 mg b.i.d. | Patient Global Impression - Improvement Scale (PGI-I). | Other | 16 Participants |
| BNC210 300 mg b.i.d. | Patient Global Impression - Improvement Scale (PGI-I). | Other | 19 Participants |
| BNC210 300 mg b.i.d. | Patient Global Impression - Improvement Scale (PGI-I). | Very Much/Much Improved | 20 Participants |
| BNC210 150 mg b.i.d. | Patient Global Impression - Improvement Scale (PGI-I). | Very Much/Much Improved | 18 Participants |
| BNC210 150 mg b.i.d. | Patient Global Impression - Improvement Scale (PGI-I). | Other | 15 Participants |
| Placebo b.i.d. | Patient Global Impression - Improvement Scale (PGI-I). | Very Much/Much Improved | 20 Participants |
| Placebo b.i.d. | Patient Global Impression - Improvement Scale (PGI-I). | Other | 10 Participants |
Secondary
Patient Global Impressions - Severity Scale (PGI-S).
Self-reported global symptom severity using the Patient Global Impressions - Severity Scale (CGI-S).
Time frame: 12 weeks.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| BNC210 600 mg b.i.d. | Patient Global Impressions - Severity Scale (PGI-S). | Normal | 11 Participants |
| BNC210 600 mg b.i.d. | Patient Global Impressions - Severity Scale (PGI-S). | Mild | 8 Participants |
| BNC210 600 mg b.i.d. | Patient Global Impressions - Severity Scale (PGI-S). | Moderate | 12 Participants |
| BNC210 600 mg b.i.d. | Patient Global Impressions - Severity Scale (PGI-S). | Severe | 2 Participants |
| BNC210 300 mg b.i.d. | Patient Global Impressions - Severity Scale (PGI-S). | Mild | 21 Participants |
| BNC210 300 mg b.i.d. | Patient Global Impressions - Severity Scale (PGI-S). | Moderate | 11 Participants |
| BNC210 300 mg b.i.d. | Patient Global Impressions - Severity Scale (PGI-S). | Severe | 1 Participants |
| BNC210 300 mg b.i.d. | Patient Global Impressions - Severity Scale (PGI-S). | Normal | 6 Participants |
| BNC210 150 mg b.i.d. | Patient Global Impressions - Severity Scale (PGI-S). | Moderate | 9 Participants |
| BNC210 150 mg b.i.d. | Patient Global Impressions - Severity Scale (PGI-S). | Mild | 14 Participants |
| BNC210 150 mg b.i.d. | Patient Global Impressions - Severity Scale (PGI-S). | Severe | 4 Participants |
| BNC210 150 mg b.i.d. | Patient Global Impressions - Severity Scale (PGI-S). | Normal | 6 Participants |
| Placebo b.i.d. | Patient Global Impressions - Severity Scale (PGI-S). | Severe | 4 Participants |
| Placebo b.i.d. | Patient Global Impressions - Severity Scale (PGI-S). | Mild | 13 Participants |
| Placebo b.i.d. | Patient Global Impressions - Severity Scale (PGI-S). | Normal | 10 Participants |
| Placebo b.i.d. | Patient Global Impressions - Severity Scale (PGI-S). | Moderate | 3 Participants |
Secondary
Post-Traumatic Stress Disorder (PTSD) Checklist for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (PCL-5).
Self-reported PTSD symptom severity. The range for the Post-Traumatic Stress Disorder (PTSD) Checklist for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (PCL-5) Symptom Severity Score is 0-80, with a higher score meaning a higher severity of disease.
Time frame: 12 weeks.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| BNC210 600 mg b.i.d. | Post-Traumatic Stress Disorder (PTSD) Checklist for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (PCL-5). | 25.02 score on a scale |
| BNC210 300 mg b.i.d. | Post-Traumatic Stress Disorder (PTSD) Checklist for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (PCL-5). | 20.99 score on a scale |
| BNC210 150 mg b.i.d. | Post-Traumatic Stress Disorder (PTSD) Checklist for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (PCL-5). | 29.97 score on a scale |
| Placebo b.i.d. | Post-Traumatic Stress Disorder (PTSD) Checklist for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (PCL-5). | 24.65 score on a scale |
Secondary
Sleep Monitoring: Pittsburgh Sleep Quality Index (PSQI).
Sleep quality and duration. The range for the Pittsburgh Sleep Quality Index (PSQI) score is 0-21, with a higher score meaning a worse level of sleep quality
Time frame: 12 weeks.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| BNC210 600 mg b.i.d. | Sleep Monitoring: Pittsburgh Sleep Quality Index (PSQI). | 8.80 score on a scale |
| BNC210 300 mg b.i.d. | Sleep Monitoring: Pittsburgh Sleep Quality Index (PSQI). | 8.83 score on a scale |
| BNC210 150 mg b.i.d. | Sleep Monitoring: Pittsburgh Sleep Quality Index (PSQI). | 9.15 score on a scale |
| Placebo b.i.d. | Sleep Monitoring: Pittsburgh Sleep Quality Index (PSQI). | 8.00 score on a scale |
Secondary
Social Functioning: Sheehan Disability Scale (SDS).
Social functioning. The range for the Total Score on the Sheehan Disability Scale (SDS) is 0-30, with a higher score meaning a higher degree of impairment.
Time frame: 12 weeks.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| BNC210 600 mg b.i.d. | Social Functioning: Sheehan Disability Scale (SDS). | 8.84 score on a scale |
| BNC210 300 mg b.i.d. | Social Functioning: Sheehan Disability Scale (SDS). | 6.66 score on a scale |
| BNC210 150 mg b.i.d. | Social Functioning: Sheehan Disability Scale (SDS). | 10.32 score on a scale |
| Placebo b.i.d. | Social Functioning: Sheehan Disability Scale (SDS). | 8.47 score on a scale |